Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Anticipated CAGR of the Low-Grade Glioma Market, and What Factors Will Drive It?

In recent times, a robust expansion has been observed in the market for low-grade glioma. The market, which stood at $1.39 billion in 2024, is forecasted to grow to $1.48 billion by 2025, with a compound annual growth rate (CAGR) of 6.1%. The factors driving this noticeable growth during the historic period include a heightened awareness about brain tumors, more investment in oncology-driven research, increased allocations for orphan drug designation, advancement in telemedicine, and the enhancement of healthcare access.

In the coming years, the market for low-grade glioma is projected to experience robust growth. With a compound annual growth rate (CAGR) of 5.9%, the market is anticipated to reach $1.86 billion by 2029. The growth during this projection period can be linked to factors such as an increasing aging population, rising spending on healthcare, growth in the incidence of brain tumors, government initiatives, and an upswing in both the incidence and prevalence of high-grade gliomas. Significant trends expected within this forecast period encompass improvements in imaging technologies, the evolution of radiation therapies, the launch of new chemotherapy regimens, expansion of clinical trials, and the addition of immunotherapy.

What Drivers Are Shaping the Growth of the Low-Grade Glioma Market?

Expected growth in the low-grade glioma market is largely due to the surge in brain tumor incidents. Brain tumors are an unusual aggregation of cells in the brain or its neighboring areas and can be benign or malignant. Factors such as heightened exposure to radiation, environmental toxins, genetic predisposition, and aging contribute to the increased occurrence of brain tumors. Low-grade glioma helps manage the said tumors, employing advanced diagnostic techniques and specialized treatments including but not limited to surgery, radiation, and chemotherapy. These treatments help control tumor progression, uphold neurological functionality, and enhance patient outcomes, stressing the importance of early detection and tailored treatment for curbing other brain tumors with similar growth habits. As an example, The Central Brain Tumor Registry of the United States (CBTRUS), a non-profit organization based in the US, reported in October 2023 that the global rate of primary malignant brain tumors in 2022 was roughly 3.5 per 100,000. It was noted that high-income countries had a higher rate (4.9 per 100,000) compared to low-middle (2.4 per 100,000) and low-income countries. Hence, this surge in brain tumor incidents is prompting the expansion of the low-grade glioma market.

Explore Comprehensive Insights Into The Global Low-Grade Glioma Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

Who Are the Top Companies Contributing to the Growth of the Low-Grade Glioma Market?

Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.

How Are Technological Trends Affecting the Growth and Development of the Low-Grade Glioma Market?

Leading businesses in the low-grade glioma market are integrating combination therapy and targeted therapy, such as drugs for genetic alterations, to solidify their market presence and improve treatments for children affected by low-grade glioma. These genetic alteration medicines are targeted treatments aimed to regulate or suppress certain gene mutations or irregularities in cells. This aids in the treatment of diseases like cancer by restricting the routes that facilitate the uncontrollable growth of cells. For example, Day One Biopharmaceuticals, an American biotech firm, launched Tovorafenib (Ojemda) in May 2024 after obtaining fast-tracked FDA approval. This targeted treatment is meant for children aged six months and above with inoperable or recurring low-grade glioma (LGG) accompanied by BRAF gene modifications. With a convenient oral intake once a week, it caters to the crucial needs of pediatric LGG patients who previously had limited treatment alternatives.

Secure Your Global Low-Grade Glioma Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

Which Segments of the Low-Grade Glioma Market Hold the Most Potential for Future Development?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Route Of Administration: Topical, Oral

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

What Are the Key Regions Powering Growth in the Low-Grade Glioma Market?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Defines the Scope of the Low-Grade Glioma Market?

Low-grade gliomas are a type of brain tumor that develops from glial cells, which provide support and insulation to nerve cells in the brain, characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still cause significant neurological symptoms and may require treatments.

Browse Through More Similar Reports By The Business Research Company:

Infertility Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/infertility-treatment-global-market-report

Fertility Treatments Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report

Urinary Tract Infection Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/urinary-tract-infection-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: